Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis

Rheumatology (Oxford, England) (Impact Factor: 4.48). 01/2014; 53(5). DOI: 10.1093/rheumatology/ket483
Source: PubMed


ANCA-associated vasculitis (AAV) commonly affects those of working age. Since survival rates have been transformed by immunotherapeutics, the measurement of other outcomes has become increasingly relevant. Work disability is an important outcome for both patient and society that has yet to be fully evaluated in AAV. We aimed to assess employment status in AAV patients and identify putative predictors of their work disability.

A cross-sectional study was undertaken. AAV cases were recruited according to consecutive clinic attendance. Subjects completed a questionnaire that determined employment status and other psychosocial measures. Clinical factors were concurrently recorded by the attending physician. From the data of those subjects of working age, a multivariable model was developed using forward stepwise logistic regression to identify the independent associations of work disability, defined by those subjects reporting unemployment secondary to ill-health. Results are expressed as odds ratios (ORs) and 95% CIs.

Of the 410 participants (84.4% response rate), 149 (36.7%) were employed, 197 (48.6%) retired and 54 (13.3%) unemployed secondary to ill health. Of those of working age, 26.0% were considered work disabled. Fatigue (OR 7.1, 95% CI 1.5, 33.1), depression (OR 4.4, 95% CI 1.8, 10.8), severe disease damage [Vasculitis Damage Index (VDI) > 4 (OR 3.9, 95% CI 1.01, 14.7)] and being overweight (OR 3.4, 95% CI 1.3, 8.9) were independently associated with their unemployment.

A quarter of working-age AAV subjects reported unemployment as a result of ill health and are characterized by high levels of fatigue, depression, disease damage and being overweight. These potentially modifiable factors may inform future multidisciplinary interventions aimed at alleviating work disability.

Download full-text


Available from: Mark Alan Little, Mar 10, 2014
102 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe the design and validation of current outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis, and provide insight into ongoing outcome measure development for future randomized controlled trials (RCTs). Substantial evidence now supports that patient-reported outcomes (PROs) capture unique disease components not represented in current physician-based measures. Further incorporation of for formal disease assessment in the setting of RCT will both improve disease assessment in terms of adding new important disease domains and could improve psychometric properties of outcome measures and, therefore, increase trial efficiency. Optimal outcome measures for AAV promote identification of therapeutic agents that treat all important disease manifestations.
    Current Opinion in Rheumatology 11/2014; 27(1). DOI:10.1097/BOR.0000000000000135 · 4.89 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction of the standard immunosuppressive treatment has dramatically changed the outcome of patients with both ANCA-associated vasculitis and lupus nephritis, transforming them from incurable diseases with very high short-term mortality to chronic debilitating diseases with much lower short-term, but still relatively high long-term, morbidity/mortality. Long-term morbidity with damage accumulating partly due to the adverse events of the available treatment (namely gonadal toxicity, malignancy, bone disease, cataracts, diabetes, and thromboembolic and cardiovascular disease) has become a major concern. Although cyclophosphamide-based regimens have been partly replaced by newer agents in both ANCA-associated vasculitis and lupus nephritis (namely rituximab or mycophenolate, respectively) their short-term and medium-term adverse events may not be significantly less frequent and we can only hope that new treatments will translate into better long-term outcomes including better long-term safety. © 2014 S. Karger AG, Basel.
    Nephron Clinical Practice 11/2014; 128(3-4). DOI:10.1159/000368569 · 1.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Granulomatosis with polyangiitis is a systemic necrotizing vasculitis characterized by granulomatous inflammation of small vessels and is associated with autoantibodies to neutrophil cytoplasmic proteases, mainly proteinase 3. Potentially lethal if not promptly diagnosed and treated, most patients with granulomatosis with polyangiitis can achieve remission with the current treatment modalities, with fewer side effects compared to three decades ago. However, the risk of relapse remains high, necessitating prolonged maintenance immunosuppressive therapy whose optimal duration remains undetermined. We review herein the treatment modalities for granulomatosis with polyangiitis and how they have evolved over the past decades. The findings of the most important and recently completed therapeutic studies, including on rituximab for maintenance, are summarized, before describing the main ongoing studies aimed at further optimizing treatment strategies.
    Expert Review of Clinical Immunology 02/2015; 11(3):1-10. DOI:10.1586/1744666X.2015.1008455 · 2.48 Impact Factor
Show more

Similar Publications